ICPT - Intercept Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Intercept Pharmaceuticals, Inc.

10 Hudson Yards
37th floor
New York, NY 10001
United States

Full Time Employees483

Key Executives

NameTitlePayExercisedYear Born
Dr. Mark PruzanskiFounder, CEO, Pres & Director1.15M4.62M1968
Mr. Sandip S. KapadiaCFO, Treasurer & Principal Accounting Officer693.14kN/A1970
Mr. Jerome B. DursoChief Operating Officer855.24kN/A1968
Mr. Ryan T. SullivanGen. Counsel & Sec.812.95kN/A1976
Dr. Gail CawkwellSr. VP of Medical Affairs, Safety & Pharmacovigilance600.85kN/A1962
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases. It markets Ocaliva, an farnesoid X receptor agonist approved in the United States, the European Union, and other jurisdictions for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults. The company is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis (NASH); and several other product candidates in various stages of clinical and preclinical development. Intercept Pharmaceuticals, Inc. has a license agreement with Sumitomo Dainippon Pharma Co. Ltd. for the research, development, and commercialization of OCA as a therapeutic for the treatment of PBC and NASH in Japan and China. The company was founded in 2002 and is headquartered in New York, New York.

Corporate Governance

Intercept Pharmaceuticals, Inc.’s ISS Governance QualityScore as of October 4, 2019 is 4. The pillar scores are Audit: 2; Board: 4; Shareholder Rights: 6; Compensation: 4.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.